RadNet trades as part of the medical diagnostics and research industry and is part of the healthcare sector. The company CEO is Howard G. Berger. RadNet Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, and among others.
Previous Intraday Performance:
The RDNT shares had a previous change of -2.23% which opened at 13.39 and closed at 13.17. It moved to an intraday high of 13.46 and a low of 13.15.
Over the last five trading days, RDNT shares returned -0.38% and in the past 30 trading days it returned 2.49%. Over three months, it changed -3.73%. In one year it has changed 1.31% and within that year its 52-week high was 16.54 and its 52-week low was 9.97. RDNT stock is 32.10% above its 52 Week Low.
Our calculations result in a 200 day moving average of 13.45 and a 50 day moving average of 13.03. Right now, RDNT stock is trading -2.10% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
The company has a market cap of $659.6m with 50.1m shares outstanding and a float of 45.3m shares. Trading volume was 172,477 shares and has experienced an average volume of 304,897 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for RadNet was 0.66 which ended on 31st of December 2018, which according to the previous close, that is a PE of 19.95. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.02. The trailing twelve month EPS is 0.78, which comes to a trailing twelve month PE of 16.88.
Base on our calculations, the intrinsic value per share is 13.01, which means it might overvalued by -1.20%
EPS growth is an important number as it indicates the future prospects of RadNet; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 6.70% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 81.20% of institutional ownership.
I calculated the beta to be 1.02
Based on last reported financials, the company’s return on equity is 34.40%, return on assets is 3.03%, profit margin is 4.54%, price-to-sales is 0.74 and price-to-book is 4.96.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
1 : Financial Safety Result
1 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
0 : Overall Result